Amyloid beta 1-42, and tau in cerebrospinal fluid after severe traumatic brain injury

被引:178
作者
Franz, G
Beer, R
Kampfl, A
Engelhardt, K
Schmutzhard, M
Ulmer, H
Deisenhammer, F
机构
[1] Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Biostat, A-6020 Innsbruck, Austria
关键词
D O I
10.1212/01.WNL.0000063313.57292.00
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine whether CSF amyloid beta 1-42 (Abeta-42) and tau have predictive value for prognosis after head injury. Methods: CSF samples were collected from 29 patients with severe head trauma between 1 and 284 days post-trauma. Abeta-42 and tau levels were measured using sandwich ELISA techniques and compared with CSF levels in patients with cognitive disorders and headache. Results: At all time points, concentrations of Abeta-42 were significantly lower in patients with traumatic brain injury (TBI) than in control groups. A significant correlation existed for Abeta-42 levels and outcome of patients. Below a cutoff of 230 pg/mL, the sensitivity of Abeta-42 to discriminate between good outcome (Glasgow Outcome Score 4 and 5) and poor outcome (Glasgow Outcome Score I through 3) was 100% at a specificity of 82%. CSF tau levels were significantly higher in patients with TBI than in any control group. In patients with multiple CSF samples collected at various time points between 1 and 32 days after the trauma, tau levels increased early after TBI, peaked in the second week post-trauma, and slowly decreased thereafter. Independent of outcome, all patients had normal tau levels when CSF was collected more than 43 days post-trauma. Conclusions: Abeta-42 and tau may play a potential role in the pathophysiology of TBI. Furthermore, the results of this study suggest that Abeta-42 may be a supportive early predictor for recovery after severe head injury.
引用
收藏
页码:1457 / 1461
页数:5
相关论文
共 29 条
  • [1] DIFFUSE AXONAL INJURY IN HEAD-INJURY - DEFINITION, DIAGNOSIS AND GRADING
    ADAMS, JH
    DOYLE, D
    FORD, I
    GENNARELLI, TA
    GRAHAM, DI
    MCLELLAN, DR
    [J]. HISTOPATHOLOGY, 1989, 15 (01) : 49 - 59
  • [2] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
    Andreasen, N
    Minthon, L
    Davidsson, P
    Vanmechelen, E
    Vanderstichele, H
    Winblad, B
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
  • [3] Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO
  • [4] 2-K
  • [5] A beta(42) is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury
    Gentleman, SM
    Greenberg, BD
    Savage, MJ
    Noori, M
    Newman, SJ
    Roberts, GW
    Griffin, WST
    Graham, DI
    [J]. NEUROREPORT, 1997, 8 (06) : 1519 - 1522
  • [6] GENTRY LR, 1994, RADIOLOGY, V191, P1
  • [7] TAU-PROTEIN IN ALZHEIMERS-DISEASE
    GOEDERT, M
    JAKES, R
    SPILLANTINI, MG
    CROWTHER, RA
    COHEN, P
    VANMECHELEN, E
    PROBST, A
    GOTZ, J
    BURKI, K
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (01) : 80 - 85
  • [8] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
    Hulstaert, F
    Blennow, K
    Ivanoiu, A
    Schoonderwaldt, HC
    Riemenschneider, M
    De Deyn, PP
    Bancher, C
    Cras, P
    Wiltfang, J
    Mehta, PD
    Iqbal, K
    Pottel, H
    Vanmechelen, E
    Vanderstichele, H
    [J]. NEUROLOGY, 1999, 52 (08) : 1555 - 1562
  • [9] JENNETT B, 1972, LANCET, V1, P734
  • [10] Prediction of recovery from post-traumatic vegetative state with cerebral magnetic-resonance imaging
    Kampfl, A
    Schmutzhard, E
    Franz, G
    Pfausler, B
    Haring, HP
    Ulmer, H
    Felber, S
    Golaszewski, S
    Alchner, F
    [J]. LANCET, 1998, 351 (9118) : 1763 - 1767